Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical and epidemiological characteristics of hepatitis C virus-infected people who inject drugs: a Greek descriptive analysis.
Kranidioti H, Chatzievagelinou C, Protopapas A, Papatheodoridi M, Zisimopoulos K, Evangelidou E, Antonakaki P, Vlachogiannakos J, Triantos C, Elefsiniotis I, Goulis J, Mela M, Anagnostou O, Tsoulas C, Deutsch M, Papatheodoridis G, Manolakopoulos S. Kranidioti H, et al. Among authors: papatheodoridi m. Ann Gastroenterol. 2018 Sep-Oct;31(5):598-603. doi: 10.20524/aog.2018.0293. Epub 2018 Jul 19. Ann Gastroenterol. 2018. PMID: 30174397 Free PMC article.
DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: papatheodoridi m. Antivir Ther. 2018;23(8):677-685. doi: 10.3851/IMP3256. Antivir Ther. 2018. PMID: 30044765
Correction: DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M, Zachou K, Xourafas V, Gatselis N, Hadziyannis E, Vlachogiannakos J, Manolakopoulos S, Dalekos GN. Papatheodoridis GV, et al. Among authors: papatheodoridi m. Antivir Ther. 2018;23(8):711. doi: 10.3851/IMP3261. Antivir Ther. 2018. PMID: 30091421 No abstract available.
Can we stop nucleoside analogues before HBsAg loss?
Papatheodoridi M, Papatheodoridis G. Papatheodoridi M, et al. J Viral Hepat. 2019 Aug;26(8):936-941. doi: 10.1111/jvh.13091. Epub 2019 Mar 27. J Viral Hepat. 2019. PMID: 30803099 Review.
Predictors of hepatitis B surface antigen loss, relapse and retreatment after discontinuation of effective oral antiviral therapy in noncirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridi M, Hadziyannis E, Berby F, Zachou K, Testoni B, Rigopoulou E, Gatselis NK, Lyberopoulou A, Vlachogiannakos I, Manolakopoulos S, Dalekos GN, Zoulim F, Papatheodoridis GV. Papatheodoridi M, et al. J Viral Hepat. 2020 Feb;27(2):118-126. doi: 10.1111/jvh.13211. Epub 2019 Oct 15. J Viral Hepat. 2020. PMID: 31562748
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B.
Papatheodoridis GV, Dalekos GN, Idilman R, Sypsa V, Van Boemmel F, Buti M, Calleja JL, Goulis J, Manolakopoulos S, Loglio A, Papatheodoridi M, Gatselis N, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Yurdaydin C, Esteban R, Janssen HLA, Berg T, Lampertico P. Papatheodoridis GV, et al. Among authors: papatheodoridi m. J Hepatol. 2020 Nov;73(5):1037-1045. doi: 10.1016/j.jhep.2020.06.011. Epub 2020 Jun 16. J Hepatol. 2020. PMID: 32553667
Current status of hepatitis delta.
Papatheodoridi M, Papatheodoridis GV. Papatheodoridi M, et al. Curr Opin Pharmacol. 2021 Jun;58:62-67. doi: 10.1016/j.coph.2021.03.008. Epub 2021 Apr 22. Curr Opin Pharmacol. 2021. PMID: 33895531 Review.
48 results